What’s the current market cap for Stryker stock?

Stryker (SYK) has a market cap of $120bn as of June 13, 2026.

What is the P/E ratio for Stryker stock?

The price to earnings (P/E) ratio for Stryker (SYK) stock is 36.13 as of June 13, 2026.

Does Stryker stock pay dividends?

Yes, the Stryker (SYK) stock pays dividends to shareholders. As of June 13, 2026, the dividend rate is $3.44 and the yield is 1.13%. Stryker has a payout ratio of 38.99% on a trailing twelve-month basis.

When is the next Stryker dividend payment date?

The next Stryker (SYK) dividend payment is scheduled for July 31, 2026.

What is the beta indicator for Stryker?

Stryker (SYK) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Stryker stock | $SYK Share Price

About Stryker

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.

Ticker

$SYK

Sector

Health

Primary listing

NYSE

Employees

56,000

Headquarters

Portage, United States

Website

www.stryker.com

Stryker Metrics

BasicAdvanced

$120bn

36.13

$8.64

0.78

$3.44

1.13%

What the Analysts think about Stryker

Analyst ratings (Buy, Hold, Sell) for Stryker stock.

Bulls say / Bears say

Stryker raised its full-year profit forecast to $14.90–$15.10 per share on Jan 22, 2026, reflecting robust Q4 performance with MedSurg & Neurotechnology sales up 17.5% and orthopedics sales up 2.2%. (Reuters)

Despite a March cyberattack that disrupted operations and delayed surgeries, Stryker maintained its 2026 adjusted EPS guidance of $14.90–$15.10 and organic sales growth target of 8%–9.5%, underscoring confidence in recovery and demand resilience. (Reuters)

Stryker’s Mako SmartRobotics platform continues to drive recurring revenue growth, with over two million procedures completed and record installations in 2025 as the company expands into spine and shoulder applications to broaden its addressable market. (Zacks)

In Q1 2026, Stryker missed Wall Street profit and revenue estimates, reporting total revenue of $6.02 billion versus the $6.35 billion consensus and adjusted EPS of $2.60 against $2.98 expected, reflecting muted demand for complex procedures. (Reuters)

Stryker anticipates roughly a $400 million tariff impact in 2026—about $200 million more than the prior year—posing a meaningful headwind to margins if not fully offset by manufacturing optimization. (Reuters)

Persistent supply chain constraints in select medical equipment categories are expected to continue through 2025, limiting the company’s ability to capitalize on strong demand and potentially undermining customer relationships. (Zacks)

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.

Stryker Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Stryker Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Stryker News

AllArticlesVideos

Stryker Launches Pangea Plating System and Completes First Case in Europe

Business Wire·3 weeks ago

BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem

Business Wire·4 weeks ago

AVS, Now Part of Stryker, Enrolls First Patient in First-in-Human Coronary Intravascular Lithotripsy Study

Business Wire·4 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.